Efficacy of Decitabine and Venetoclax as Salvage and Bridge Therapy to Haploidentical Hematopoietic Stem Cell Transplantation in a Multiresistant Acute Myeloid Leukemia Patient

Bianca Serio; Valentina Giudice; Denise Morini; Roberto Guariglia; Rosa Vitolo; Paola Manzo; Maddalena Langella; Carmine Selleri

doi:10.1159/000524952

Efficacy of Decitabine and Venetoclax as Salvage and Bridge Therapy to Haploidentical Hematopoietic Stem Cell Transplantation in a Multiresistant Acute Myeloid Leukemia Patient

Case Rep Oncol. 2022 Jun 7;15(2):593-598. doi: 10.1159/000524952. eCollection 2022 May-Aug.

Authors

Bianca Serio¹, Valentina Giudice^{1

2}, Denise Morini¹, Roberto Guariglia¹, Rosa Vitolo¹, Paola Manzo¹, Maddalena Langella¹, Carmine Selleri^{1

2}

Affiliations

¹ Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona,", Salerno, Italy.
² Department of Medicine, Surgery, and Dentistry, University of Salerno, Baronissi, Italy.

Abstract

Treatment of relapsed/refractory or elderly unfit acute myeloid leukemia (AML) is still challenging, and hypomethylating agents in combination with venetoclax, an oral selective BCL2 inhibitor, might be successfully used as salvage therapy. However, clinical trials evaluating the efficacy and safety of this combination in the setting of multiresistant AML treatment also as a bridge to transplant are still ongoing. Here, we reported a 50-year-old male diagnosed with AML with normal cytogenetics and wild type for fms-like tyrosine kinase 3, nucleophosmin 1, and KIT, and treated with decitabine and venetoclax as the fifth line of therapy and after a relapse post-allogeneic transplant. The patient achieved a complete remission and successfully underwent a haploidentical transplant with an overall survival of 48.6 months.

Keywords: Acute myeloid leukemia; BCL2 inhibitor; Hematopoietic stem cell transplantation; Hypomethylating agents; Salvage therapy.

Publication types

Case Reports